Loading news...
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
SG Americas Securities LLC cut its holdings in Alkermes plc (NASDAQ: ALKS) by 49.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,617 shares of the company's stock after selling 30,225 shares during the period. SG Americas
Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GES, NESR and ALKS made it to the Zacks Rank #1 (Strong Buy) value stocks list on Jan.14, 2026.
Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (“Avadel” or the “Company”) announces today that, in relation to the previously announced offer for the Company by Alkermes plc, a public limited company incorporated in Ireland (“Alkermes”), pursuant to which Alkermes will acquire the entire issued and to be issued ordinary share capital of the Company (the “Proposed Transaction”), the resolutions required to approve the scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Scheme”) were passed by the requisite majorities at the scheme meeting of shareholders (the “Scheme Meeting”) and the related extraordinary general meeting of shareholders (“EGM”) held earlier today.
Alkermes plc (NASDAQ: ALKS - Get Free Report) EVP Craig Hopkinson sold 5,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the executive vice president owned 61,740 shares of
Robeco Institutional Asset Management B.V. lifted its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 18.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 134,387 shares of the company's stock after purchasing an additional 21,067 shares during the quarter. Robeco Institutional
Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton's Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline.
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating alixorexton in patients with NT1. Alixorexton is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in developm.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth.
NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Edgestream Partners L.P. reduced its holdings in Alkermes plc (NASDAQ: ALKS) by 33.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 73,898 shares of the company's stock after selling 36,346 shares during the quarter. Edgestream Partners L.P.'s holdings in Alkermes
Capital Fund Management S.A. bought a new stake in Alkermes plc (NASDAQ: ALKS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 39,929 shares of the company's stock, valued at approximately $1,142,000. Other large investors have also modified
Fisher Asset Management LLC lessened its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 9.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 291,947 shares of the company's stock after selling 29,734 shares during the quarter. Fisher Asset Management LLC owned